IRWD (Ironwood Pharmaceuticals) Insider Ownership: 8.05 % (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.11
GF Value $4.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Insider Ownership?

Ironwood Pharmaceuticals IRWD -6.06% 65 Insider Ownership is 8.05 % as of Aug. 20, 2026. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.55 (Fairly Valued). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's insider ownership is 8.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ironwood Pharmaceuticals's Institutional Ownership is 97.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 91.54%.

Ironwood Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Ironwood Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals Insider Ownership Chart

Ironwood Pharmaceuticals Historical Data

The historical data trend for Ironwood Pharmaceuticals can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 7.30 7.26 7.39 7.39 7.38 7.38 7.17 7.79 8.05 8.05
IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ironwood Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.05 % mean?
Ironwood Pharmaceuticals (IRWD) has a Insider Ownership of 8.05 % as of Aug. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Ironwood Pharmaceuticals and its competitors.
Is Ironwood Pharmaceuticals' Insider Ownership too high?
Ironwood Pharmaceuticals' current Insider Ownership is 8.05 %. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Insider Ownership compare to TLRY and AQST?
Ironwood Pharmaceuticals' Insider Ownership of 8.05 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Ironwood Pharmaceuticals and its competitors. Ironwood Pharmaceuticals's current Insider Ownership is 8.05 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Fairly Valued. The stock's GF Value™ is $4.55, compared to a current price of $4.11 — trading 9.8% below its estimated fair value. The current Insider Ownership is 8.05 %. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Insider Ownership is 8.05 % as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.11 is trading 9.8% below its estimated GF Value™ of $4.55. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Insider Ownership: 8.05 %
  • GF Value™: $4.55 vs. price of $4.11 (9.8% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$4.55
GF Value